EyePoint Pharmaceuticals and Equinox Science have signed an exclusive license agreement for the development of vorolanib, according to a press release.
Vorolanib, a tyrosine kinase inhibitor, is being developed as EYP-1901 for the treatment of wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion using EyePoint’s bioerodible Durasert technology.
“EyePoint is dedicated to developing and commercializing innovative treatments for ocular diseases, and we are very excited about the potential for EYP-1901 as a vital, new 6-month treatment for serious eye
Uncategorized